Skip to content

Aethl Bio

1 viewer · 30d

Total raised

$1.6M

1 filing since 2025 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $1.6M
ROUNDS
1
INVESTORS
8
FOUNDED
2025
HQ
Pittsburgh, PA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Aethl Bio is a Pittsburgh biotechnology company developing hydrogel-based products for chronic wound care and wellness. Its proprietary hyper-oxygenated solution platform is designed to deliver biologically relevant oxygen to tissue to support healing and functional skin recovery rather than wound closure alone. The company was founded in 2025 by Carmelo R. Montalvo, Dan Willis, Zach Richert and Derek Gonano, and in April 2026 signed a manufacturing collaboration MOU with Pure Source, an FDA-registered contract manufacturer, while retaining ownership of its IP and formulations.

What sets it apart

A hyper-oxygenated hydrogel platform aimed at restoring skin function and reducing recurrence, rather than only closing the wound.

Funding history

1 round
SAFE+1Jul 14, 2025
Form D
+$1.6M$1.6M total

Latest SEC filings

via EDGAR · CIK 0002116929
Form D · Jul 14, 2025View on EDGAR

Products

1 tracked

Hyper-Oxygenated Solution Platform

Wound care product platform

A proprietary hydrogel formulation platform that delivers biologically relevant oxygen to wounded or compromised skin, offered in formats for medical wound care and wellness applications.

  • Hydrogel delivery of biologically relevant oxygen to tissue
  • Formats spanning both medical wound care and consumer wellness
  • Company retains full ownership of IP, formulations and product specifications
  • Contract manufacturing through an FDA-registered partner (Pure Source)

Links

WebsiteLinkedInSEC EDGAR filings